(R)-Gossypol
- Generic Name
- (R)-Gossypol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H30O8
- CAS Number
- 90141-22-3
- Unique Ingredient Identifier
- 8DY2X8LXW4
- Background
(R)-Gossypol is the R-isomer of Gossypol.
- Associated Conditions
- -
- Associated Therapies
- -
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Adult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-cell LymphomaContiguous Stage II Adult Burkitt LymphomaContiguous Stage II Adult Diffuse Large Cell LymphomaContiguous Stage II Adult Diffuse Mixed Cell LymphomaContiguous Stage II Adult Diffuse Small Cleaved Cell LymphomaContiguous Stage II Adult Immunoblastic Large Cell LymphomaContiguous Stage II Adult Lymphoblastic LymphomaContiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular Lymphoma
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00891072
- Locations
- ๐บ๐ธ
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
- Conditions
- Recurrent Adrenocortical CarcinomaStage III Adrenocortical CarcinomaStage IV Adrenocortical Carcinoma
- Interventions
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT00848016
- Locations
- ๐บ๐ธ
University of Southern California, Los Angeles, California, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- Conditions
- Extensive Stage Small Cell Lung CancerRecurrent Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00773955
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
- Conditions
- Extensive Stage Small Cell Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT00544596
- Locations
- ๐บ๐ธ
UW Health Oncology - 1 South Park, Madison, Wisconsin, United States
๐บ๐ธUniversity of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
๐บ๐ธSanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
- Conditions
- Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
- Interventions
- Drug: R-(-)-gossypol acetic acidOther: laboratory biomarker analysis
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 56
- Registration Number
- NCT00540722
- Locations
- ๐บ๐ธ
University of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.